A Look Ahead: Bio-Techne's Earnings Forecast - Nasdaq

Oct 29, 2024 · Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.Analysts anticipate Bio-Techne to ...

9%
OFF

What You Need To Know Ahead Of Bio-Techne's Earnings Release

2 weeks from now

Oct 16, 2024 · Ahead of this event, analysts project the biotech company to report a profit of $0.34 per share, down 2.9% from $0.35 per share in the year-ago quarter. The company has …

nasdaq.com

6%
OFF

Bio-Techne Corporation Just Recorded A 7.6% EPS Beat: Here's …

2 weeks from now

May 4, 2024 · The company beat expectations with revenues of US$303m arriving 3.6% ahead of forecasts. Statutory earnings per share (EPS) were US$0.31, 7.6% ahead of estimates.

yahoo.com

4%
OFF

Bio-Techne First Quarter 2025 Earnings: Beats Expectations

2 weeks from now

Nov 1, 2024 · Bio-Techne Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 2.9%. …

simplywall.st

1%
OFF

Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations

2 weeks from now

Aug 9, 2024 · Bio-Techne EPS Misses Expectations. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.1%. Looking ahead, revenue is …

simplywall.st

2%
OFF

Earnings Call: Bio-Techne Sees Growth In Q3 With Strong Market ...

2 weeks from now

Bio-Techne (NASDAQ: TECH) Corporation (NASDAQ: TECH) reported a 2% year-over-year organic revenue growth for the third quarter of fiscal year 2024, with a notable increase in …

investing.com

5%
OFF

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up In

2 weeks from now

Oct 30, 2024 · Bio-Techne TECH reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The company …

nasdaq.com

09%
OFF

A Look Ahead: Avantor's Earnings Forecast - Nasdaq

2 weeks from now

Oct 24, 2024 · As per analysts' assessments, Bio-Techne is favoring an Buy trajectory, with an average 1-year price target of $82.33, suggesting a potential 247.09% upside. Overview of …

nasdaq.com

4%
OFF

How Is Bio-Techne’s Stock Performance Compared To Other

2 weeks from now

Dec 23, 2024 · In the competitive arena of life sciences tool and services, Bio-Rad Laboratories, Inc. () has taken the lead over TECH, showing resilience with 1.4% gains on a YTD basis and …

nasdaq.com

81%
OFF

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

2 weeks from now

Nov 11, 2024 · Per the Earnings Trends report, as of Nov. 6, 81% of the companies in the Medical sector — representing 90.8% of the sector’s market capitalization — reported quarterly …

nasdaq.com

FAQs about A Look Ahead: Bio-Techne's Earnings Forecast - Nasdaq Coupon?

Did Bio-Techne (Tech) beat analyst expectations?

Bio-Techne Corporation ( NASDAQ:TECH) defied analyst predictions to release its quarterly results, which were ahead of market expectations. The company beat expectations with revenues of US$303m arriving 3.6% ahead of forecasts. Statutory earnings per share (EPS) were US$0.31, 7.6% ahead of estimates. ...

What will Bio-Techne's earnings look like in 2025?

View our latest analysis for Bio-Techne After the latest results, the twelve analysts covering Bio-Techne are now predicting revenues of US$1.25b in 2025. If met, this would reflect a solid 8.2% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 8.1% to US$1.40. ...

Will Bio-Techne's first-quarter earnings decline to 38 cents?

The Zacks Consensus Estimate for the company’s first-quarter fiscal 2025 EPS suggests a 7.3% decline to 38 cents. Estimates for Bio-Techne’s first-quarter earnings have moved down 15.5% to 38 cents in the past 90 days. ...

Will Bio-Techne's revenue growth slow?

We would highlight that Bio-Techne's revenue growth is expected to slow, with the forecast 6.5% annualised growth rate until the end of 2025 being well below the historical 12% p.a. growth over the last five years. ...

What is the Zacks consensus estimate for Bio-Techne?

For the fiscal first quarter, the Zacks Consensus Estimate for Bio-Techne’s revenues is pegged at $280.9 million, indicating an increase of 1.4% from the year-ago reported figure. The Zacks Consensus Estimate for the company’s first-quarter fiscal 2025 EPS suggests a 7.3% decline to 38 cents. ...

Is Bio-Techne a good stock to buy?

Since Bio-Techne’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market. What kind of growth will Bio-Techne generate? ...